Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 2—February 2025
Online Report

Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics

Josephine BournerComments to Author , Michel Vaillant, Alex Paddy Abdel Salam, Marie Jaspard, Camille Fritzell, Shevin T. Jacob, Tom E. Fletcher, Michael Ramharter, Nnennaya Ajayi, Sylvanus Okogbenin, Cyril Erameh, Donald Grant, Robert Samuels, Oladele Oluwafemi Ayodeji, Armand Sprecher, Bronner P. Gonçalves, Tansy Edwards, Piero Olliaro, and the WALC Work Package 2 Working Group
Author affiliation: University of Oxford, Oxford, UK (J. Bourner, A.P.A. Salam, B.P. Gonçalves, P. Olliaro); Luxembourg Institute of Health, Strassen, Luxembourg (M. Vaillant); Sorbonne Université, Paris, France (M. Jaspard); St Antoine Hospital, Paris (M. Jaspard); The Alliance for International Medical Action, Dakar, Senegal (M. Jaspard); Inserm, Bordeaux, France (C. Fritzell); Liverpool School of Tropical Medicine, Liverpool, UK, S.T. Jacob, T.E. Fletcher); University Medical Center Hamburg-Eppendorf, Hamburg, Germany (M. Ramharter); German Center for Infection Research, Riems, Germany (M. Ramharter); Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Nigeria (N. Ajayi); Irrua Specialist Teaching Hospital, Irrua, Nigeria (S. Okogbenin, C. Erameh); Kenema General Hospital, Kenema, Sierra Leone (D. Grant, R. Samuels); Federal Medical Centre, Owo, Nigeria (O.O. Ayodeji); Médecins sans Frontières, Brussels, Belgium (A. Sprecher); London School of Hygiene and Tropical Medicine, London, UK (T. Edwards)

Main Article

Table 2

West Africa Lassa fever Consortium stakeholder roles and regions in which their organizations were based

Stakeholder role Total No. (%) persons
West Africa Pan-Africa Outside Africa* International
Clinical researchers† 15 1 (7) 0 14 (93) 0
Clinician‡ 7 7 (100) 0 0 0
Drug developer 3 0 0 3 (100) 0
Ethics committee 2 2 (100) 0 0 0
Nongovernment organization 9 8 (89) 0 0 1 (11)
Public health agency 11 9 (82) 1 (9) 0 1 (9)
Regulatory body 1 0 1 (100) 0 0
Social scientists 5 5 (100) 0 0 0
Statisticians 3 0 0 3 (100) 0
Total 56 32 (57) 2 (4) 20 (36) 2 (4)

*Organizations based in Europe and the United States. †Primary function at their organization was research, but many also held clinical roles. ‡Primary function at their organization was patient management, but all conducted research.

Main Article

Page created: January 15, 2025
Page updated: January 21, 2025
Page reviewed: January 21, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external